Suppr超能文献

[卡托普利治疗高血压患者不同阶段激肽系统成分及血浆肾素活性的变化]

[Changes of components in the kinin system and plasma renin activity during different stages of hypertension in patients treated with captopril].

作者信息

Kolber-Postepska B, Zebrowska-Lupina I, Markiewicz M, Horubała-Bielak G

机构信息

Kliniki Kardiologii, Lublinie.

出版信息

Pol Tyg Lek. 1994;49(10-11):245-8.

PMID:7862589
Abstract

The authors aim was to evaluate if the changes in the components of the plasma kinin system on PRA, determined during 3-weeks period of treatment with captopril in daily doses of 150 mg, depend on the stage of arterial hypertension. Investigations were carried out in 40 patients with primary hypertension; 6 patients were in I, 20 in II and 14 in III WHO stage. The control group consisted of 18 healthy persons. All the parameters were examined 3 times: before therapy, after 24 h and after 3 weeks of therapy. It was proved that captopril as monotherapy, was effective in every stage of hypertension, however the normalisation of blood pressure was observed only in I and II WHO stage. The normalisation of the prekallikrein levels appeared after 3 weeks of treatment in all periods of hypertension, while the normalisation of the kininogen levels occurred only in patients of I and II WHO stage. Since changes of kininogen level in plasma occurred along with changes in blood pressure, therefore the estimation of kininogen seems to be better criterium of effectiveness of captorpil than the determination of prekallikrein. The changes of PRA were similar in all stages of hypertension, but they were significant only in the group of patients of II WHO stage and only after 24 h. Presented studies indicate that renin-angiotensin-aldosterone system as well as kinin system, participate in the mechanism of antihypertensive effect of captopril in every stage of hypertension.

摘要

作者的目的是评估在每日剂量为150毫克的卡托普利治疗3周期间所测定的血浆激肽系统成分变化对原发性醛固酮增多症(PRA)的影响是否取决于动脉高血压的阶段。对40例原发性高血压患者进行了研究;其中6例处于世界卫生组织(WHO)I期,20例处于II期,14例处于III期。对照组由18名健康人组成。所有参数均检查3次:治疗前、治疗24小时后和治疗3周后。结果证明,卡托普利作为单一疗法在高血压的各个阶段均有效,但仅在WHO I期和II期观察到血压正常化。在高血压各期治疗3周后前激肽释放酶水平均恢复正常,而激肽原水平仅在WHO I期和II期患者中恢复正常。由于血浆中激肽原水平的变化与血压变化同时发生,因此激肽原的评估似乎比前激肽释放酶的测定更能作为卡托普利疗效的标准。高血压各期PRA的变化相似,但仅在WHO II期患者组中且仅在24小时后才具有显著性。目前的研究表明,肾素-血管紧张素-醛固酮系统以及激肽系统参与了卡托普利在高血压各阶段的降压作用机制。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验